Research programme: aurora kinase inhibitors - ELARA
Latest Information Update: 16 Jul 2016
At a glance
- Originator Elara Pharmaceuticals
- Class
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in Germany
- 06 Aug 2009 Early research in Solid tumours in Germany (unspecified route)